NCT05223868

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 255 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Detailed description

The populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and psoriatic arthritis (PsA) and this study evaluates JNJ-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\<=) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Safety will be assessed by adverse events (AEs), clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	JNJ-77242113	JNJ-77242113 tablet will be administered orally.
DRUG	Placebo	Placebo tablet will be administered orally.

Timeline

• Start date: 2022-02-03
• Primary completion: 2022-12-15
• Completion: 2022-12-15
• First posted: 2022-02-04
• Last updated: 2026-02-13
• Results posted: 2025-12-30

Locations

76 sites across 10 countries: United States, Canada, France, Germany, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study